Preview

Научно-практическая ревматология

Расширенный поиск

Современные международные рекомендации по диагностике и лечению системной красной волчанки с ювенильным дебютом

https://doi.org/10.14412/1995-4484-2018-405-415

Полный текст:

Аннотация

Системная красная волчанка (СКВ) с дебютом в детском и подростковом возрасте представляет существенную проблему в практике педиатров и ревматологов ввиду диагностических сложностей, особенностей течения и большей вероятности неблагоприятного прогноза. До 20% больных СКВ заболевают в возрасте младше 18 лет. Только у 13% пациентов с ювенильным дебютом во взрослом состоянии имеется безмедикаментозная ремиссия при более низком, чем в популяционном контроле, качестве жизни. Статья посвящена обсуждению последних международных рекомендаций по диагностике, мониторингу и лечению СКВ у детей и подростков, опубликованных в 2017 г., с комментариями, основанными на данных литературы и на практическом опыте ведения подобных пациентов.

Об авторах

М. И. Каледа
ФГБНУ «Научноисследовательский институт ревматологии им. В.А. Насоновой», Москва
Россия


И. П. Никишина
ФГБНУ «Научноисследовательский институт ревматологии им. В.А. Насоновой», Москва
Россия


Список литературы

1. Groot N, Graeff ND, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis. Published Online First: 19 June 2017. doi: 10.1136/annrheumdis-2016-210960

2. Bandeira M, Buratti S, Bartoli M, et al. Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus. 2006;15:515-20. doi: 10.1191/0961203306lu2316oa

3. Brunner HI, Gladman DD, Ibanez D, et al. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008;58:556-62. doi: 10.1002/art.23204

4. Hersh AO, von Scheven E, Yazdany J, et al. Differences in longterm disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2009;61:13-20. doi: 10.1002/art.24091

5. Livingston B, Bonner A, Pope J. Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus. 2011;20:1345-55. doi: 10.1177/0961203311416694

6. Ramirez Gomez LA, Uribe Uribe O, Osio Uribe O, et al. Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. Lupus. 2008;17:596-604. doi: 10.1177/0961203307088006

7. Sag E, Tartaglione A, Batu ED, et al. Performance of the new SLICC classification criteria in childhood systemic lupus erythematosus: a multicentre study. Clin Exp Rheumatol. 2014;32:440-4.

8. Fonseca AR, Gaspar-Elsas MI, Land MG, et al. Comparison between three systems of classification criteria in juvenile systemic lupus erythematous. Rheumatology. 2015;54:241-7. doi: 10.1093/rheumatology/keu278

9. Mina R, Brunner HI. Pediatric lupus – are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin N Am. Genetics. 2010;36:53-80. vii-viii.

10. Hiraki LT, Feldman CH, Liu J, et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum. 2012;64:2669-76.

11. doi: 10.1002/art.34472

12. Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol. 2010;6:538-46. doi: 10.1038/nrrheum.2010.121

13. Pineles D, Valente A, Warren B, et al. Worldwide incidence and prevalence of pediatric onset systemic lupus erythematosus. Lupus. 2011;20:1187-92. doi: 10.1177/0961203311412096

14. Huemer C, Huemer M, Dorner T, et al. Incidence of pediatric rheumatic diseases in regional population in Austria. J Rheumatol. 2001;28:2116-9.

15. Kaipiainen-Seppä nen O, Savolainen A. Incidence of chronic juvenile rheumatic diseases in Finland during 1980-1990. Clin Exp Rheumatol. 1996;14:441-4.

16. Lopez P, Mozo L, Gutierrez C, et al. Epidemiology of systemic lupus erythematosus in a northern spanish population: gender and age influence on immunological features. Lupus. 2003;12:860-5. doi: 10.1191/0961203303lu469xx

17. Nightingale AL, Farmer RD, de Vries CS. Incidence of clinically diagnosed systemic lupus erythematosus 1992-1998 using the UK General Practice Research Database. Pharmacoepidemiol Drug Saf. 2006;15:656-61. doi: 10.1002/pds.1199

18. Pelkonen PM, Jalanko HJ, Lantto RK, et al. Incidence of systemic connective tissue diseases in children: a nationwide prospective study in Finland. J Rheumatol. 1994;21:2143-6.

19. Series OR. List of rare diseases and synonyms listed in alphabetical order: orphanet, 2016. Available from: http://www.orpha.net/orphacom/cahiers/docs/GB/List_of_rare_ diseases_in_alphabetical_order.pdf (cited 2016 20-01-2017).

20. Wulffraat NM, Vastert B, and SHARE Consortium. Time to share. Pediatr Rheumatol Online J. 2013;11:5. doi: 10.1186/1546-0096-11-5

21. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725. doi: 10.1002/art.1780400928

22. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for Systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677-86. doi: 10.1002/art.34473

23. Costenbader KH, Schur PH. We Need Better Classification and Terminology for «People at High-risk of or in the Process of Developing Lupus». Arthritis Care Res. 2015;67(5):593-6. doi: 10.1002/acr.22484

24. Alarcon GS, McGwin G Jr, Roseman JM, et al. Systemic lupus erythematosus in three ethnic groups. XIX. Natural history of the accrual of the American College of Rheumatology criteria prior to the occurrence of criteria diagnosis. Arthritis Rheum. 2004 Aug 15;51(4):609-15. doi: 10.1002/art.20548

25. Swaak AJ, van de Brink H, Smeenk RJ, et al; Study group on incomplete SLE and SLE with disease duration longer than 10 years... Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology (Oxford). 2001;40:89-94. doi: 10.1093/rheumatology/40.1.89

26. Abdwani R, Rizvi SG, El-Nour I. Childhood systemic lupus erythematosus in Sultanate of Oman: demographics and clinical analysis. Lupus. 2008;17:683-6. doi: 10.1177/0961203307087611

27. Bader-Meunier B, Armengaud JB, Haddad E, et al. Initial presentation of childhood-onset systemic lupus erythematosus:

28. a French multicenter study. J Pediatr. 2005 May;146(5):648-53. doi: 10.1016/j.jpeds.2004.12.045

29. Buoncompagni A, Barbano GC, Pistoia V, et al. Childhood systemic lupus erythematosus: a review of 30 cases. Clin Exp Rheumatol. 1991;9:425-30.

30. Chiang LL, Lin YT, Chan HY, et al. Differential manifestations of prepubescent, pubescent and postpubescent pediatric patients with systemic lupus erythematosus: a retrospective study of

31. chinese children and adolescents. Pediatr Rheumatol Online J. 2012;10:12. doi: 10.1186/1546-0096-10-12

32. Hiraki LT, Benseler SM, Tyrrell PN, et al. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr. 2008;152:550-6. doi: 10.1016/j.jpeds.2007.09.019

33. Olowu W. Childhood-onset systemic lupus erythematosus. J Natl Med Assoc. 2007;99:777-84.

34. Watson L, Leone V, Pilkington C, et al. Disease activity, severity, and damage in the UK Juvenile-Onset systemic lupus Erythematosus Cohort. Arthritis Rheum. 2012;64:2356-65.

35. doi: 10.1002/art.34410

36. Campos LM, Kiss MH, Scheinberg MA, et al. Antinucleosome antibodies in patients with juvenile systemic lupus erythematosus. Lupus. 2006;15:496-500. doi: 10.1191/0961203306lu2317oa

37. Hinze CH, Suzuki M, Klein-Gitelman M, et al. Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum. 2009;60:2772-81. doi: 10.1002/art.24751

38. Jesus AA, Campos LM, Liphaus BL, et al. Anti-C1q, anti-chromatin/nucleosome, and anti-dsDNA antibodies in juvenile systemic lupus erythematosus patients. Rev Bras Reumatol. 2012;52:976-81. doi: 10.1590/S0482-50042012000600015

39. Jesus AA, Silva CA, Carneiro-Sampaio M, et al. Anti-C1q antibodies in juvenile-onset systemic lupus erythematosus. Ann N Y Acad Sci. 2009;1173:235-8. doi: 10.1111/j.1749-6632.2009.04675.x

40. Jurencak R, Fritzler M, Tyrrell P, et al. Autoantibodies in pediatric systemic lupus erythematosus: ethnic grouping, cluster analysis, and clinical correlations. J Rheumatol. 2009;36:416-21. doi: 10.3899/jrheum.080588

41. Lehman TJ, Hanson V, Singsen BH, et al. The role of antibodies directed against double-stranded DNA in the manifestations of systemic lupus erythematosus in childhood. J Pediatr. 1980;96:657-61. doi: 10.1016/S0022-3476(80)80733-5

42. Tang X, Huang Y, Deng W, et al. Clinical and serologic correlations and autoantibody clusters in systemic lupus erythematosus: a retrospective review of 917 patients in South China. Medicine. 2010;89:62-7. doi: 10.1097/MD.0b013e3181cb449c

43. Wu FQ, Zhao Q, Cui XD, et al. C1q and anti-C1q antibody levels are correlated with disease severity in chinese pediatric systemic lupus erythematosus. Rheumatol Int. 2011;31:501-5.

44. doi: 10.1007/s00296-009-1257-0

45. Wu JF, Yang YH, Wang LC, et al. Antinucleosome antibodies correlate with the disease severity in children with systemic lupus erythematosus. J Autoimmun. 2006;27:119-24.

46. doi: 10.1016/j.jaut.2006.07.001

47. McHardy KC, Horne CH, Rennie J. Antinuclear antibody-negative systemic lupus erythematosus-how common? J Clin Pathol. 1982;35:1118-21. doi: 10.1136/jcp.35.10.1118

48. Gladman DD, Chalmers A, Urowitz MB. Systemic lupus erythematosus with negative LE cells and antinuclear factor. J Rheumatol. 1978;5:142-7.

49. Kavanaugh A, Tomar R, Reveille J, et al. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoanti-bodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med. 2000;124:71-81.

50. Crow YJ. Lupus: how much «complexity» is really (just) genetic heterogeneity? Arthritis Rheum. 2011;63:3661-4. doi: 10.1002/art.30603

51. Bader-Meunier B, Cave H, Jeremiah N, et al. Are RASopathies new monogenic predisposing conditions to the development of systemic lupus erythematosus? Case report and systematic review of the literature. Semin Arthritis Rheum. 2013;43:217-9.

52. doi: 10.1016/j.semarthrit.2013.04.009

53. Al-Mayouf SM, Abanomi H, Eldali A. Impact of C1q deficiency on the severity and outcome of childhood systemic lupus erythematosus. Int J Rheum Dis. 2011;14:81-5. doi: 10.1111/j.1756-185X.2010.01574.x

54. Pickering MC, Botto M, Taylor PR, et al. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol. 2000;76:227-324. doi: 10.1016/S0065-2776(01)76021-X

55. Ciftci E, Yalcinkaya F, Ince E, et al. Pulmonary involvement in childhoodonset systemic lupus erythematosus: a report of five cases. Rheumatology. 2004;43:587-91. doi: 10.1093/rheumatology/keh120

56. De Jongste JC, Neijens HJ, Duiverman EJ, et al. Respiratory tract disease in systemic lupus erythematosus. Arch Dis Child. 1986;61:478-83. doi: 10.1136/adc.61.5.478

57. Beresford MW, Cleary AG, Sills JA, et al. Cardio-pulmonary involvement in juvenile systemic lupus erythematosus. Lupus. 2005;14:152-8. doi: 10.1191/0961203305lu2073oa

58. Ahmed AM, El-Shamaa MF. Asymptomatic cardiac involvement in children with systemic lupus erythematosus. J Med Sci. 2006;6:944-9. doi: 10.3923/jms.2006.944.949

59. Cerveri I, Fanfulla F, Ravelli A, et al. Pulmonary function in children with systemic lupus erythematosus. Thorax. 1996;51:424-8. doi: 10.1136/thx.51.4.424

60. Al-Abbad AJ, Cabral DA, Sanatani S, et al. Echocardiography and pulmonary function testing in childhood onset systemic lupus erythematosus. Lupus. 2001;10:32-7. doi: 10.1191/096120301669980721

61. El-Dessoky El Shahawy E, Mosby AF, Algoubashy AA, et al. pleuropulmonary manifestations in juvenile onset systemic lupus erythematosus: assessment by pulmonary function tests and multidetector computed tomography. Egypt Rheumatologist. 2011;33:163-9. doi: 10.1016/j.ejr.2011.06.001

62. Gazarian M, Feldman BM, Benson LN, et al. Assessment of myocardial perfusion and function in childhood systemic lupus erythematosus. J Pediatr. 1998;132:109-16. doi: 10.1016/S0022-3476(98)70494-9

63. Trapani S, Camiciottoli G, Ermini M, et al. Pulmonary involvement in juvenile systemic lupus erythematosus: a study on lung function in patients asymptomatic for respiratory disease. Lupus. 1998;7:545-50. doi: 10.1191/096120398678920631

64. Parodi A, Davi S, Pringe AB, et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum. 2009;60:3388-99. doi: 10.1002/art.24883

65. Bennett TD, Fluchel M, Hersh AO, et al. Macrophage activation syndrome in children with systemic lupus erythematosus and children with juvenile idiopathic arthritis. Arthritis Rheum. 2012;64:4135-42. doi: 10.1002/art.34661

66. Mina R, Klein-Gitelman MS, Nelson S, et al. Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus. Ann Rheum Dis. 2014;73:401-6. doi: 10.1136/annrheumdis-2012-202376

67. Mina R, Klein-Gitelman MS, Ravelli A, et al. Inactive disease and remission in childhood-onset systemic lupus erythematosus. Arthritis Care Res. 2012;64:683-93. doi: 10.1002/acr.21612

68. Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR standing Committee for International clinical studies including therapeutics. Ann Rheum Dis. 2008;67:195-205. doi: 10.1136/ard.2007.070367

69. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League against Rheumatism and european renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771-82. doi: 10.1136/annrheumdis-2012-201940

70. Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69:1269-74. doi: 10.1136/ard.2009.117200

71. Gutierrez-Suarez R, Ruperto N, Gastaldi R, et al. A proposal for a pediatric version of the systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index based on the analysis of 1,015 patients with juvenile onset systemic lupus erythematosus. Arthritis Rheum. 2006;54:2989-96. doi: 10.1002/art.22048

72. Rygg M, Pistorio A, Ravelli A, et al. A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus. Ann Rheum Dis. 2012;71:511-7. doi.: 10.1136/annrheumdis-2011-200106

73. Brunner HI, Higgins GC, Klein-Gitelman MS, et al. Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus. Arthritis Care Res. 2010;62:950-9. doi: 10.1002/acr.20154

74. Brunner HI, Silverman ED, Bombardier C, et al. European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 2003;49:335-41. doi: 10.1002/art.11111

75. Lattanzi B, Consolaro A, Solari N, et al. Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic lupus activity measure (SLAM), Systemic lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). Arthritis Care Res. 2011;63(Suppl 11):112-7. doi: 10.1002/acr.20623

76. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288-91.

77. Marks SD, Pilkington C, Woo P, et al. The use of the British Isles Lupus Assessment Group (BILAG) index as a Valid tool in assessing disease activity in childhood-onset Systemic lupus erythematosus. Rheumatology. 2004;43:1186-9. doi: 10.1093/rheumatology/keh284

78. Al-Mayouf SM, Al-Hemidan AI. Ocular manifestations of SLE in children. Saudi Med J. 2003;24:964-6.

79. Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66:1560-7. doi: 10.1136/ard.2007.072157

80. Marmor MF, Kellner U, Lai TY, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopa-thy. Ophthalmology. 2011;118:415-22. doi: 10.1016/j.ophtha.2010.11.017

81. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69:20-8.

82. doi: 10.1136/ard.2008.101766

83. Ziering CL, Rabinowitz LG, Esterly NB. Antimalarials for children: indications, toxicities, and guidelines. J Am Acad Dermatol. 1993;28(5 Pt 1):764-70. doi: 10.1016/0190-9622(93)70107-5

84. ACR. Position statement: screening for Hydroxychloroquine Retinopathy, 2011.

85. Stege H, Budde MA, Grether-Beck S, et al. Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing the photoprovocation test. Photodermatol Photoimmunol Photomed. 2000;16:256-9. doi: 10.1034/j.1600-0781.2000.160604.x

86. Lawson EF, Hersh AO, Applebaum MA, et al. Self-management skills in adolescents with chronic rheumatic disease: a cross-sectional survey. Pediatr Rheumatol Online J. 2011;9:35.

87. doi: 10.1186/1546-0096-9-35

88. Felsenstein S, Reiff AO, Ramanathan A. Transition of Care and Health-Related Outcomes in Pediatric-Onset systemic lupus erythematosus. Arthritis Care Res. 2015;67:1521-8. doi: 10.1002/acr.22611

89. Tucker LB, Cabral DA. Transition of the adolescent patient with rheumatic disease: issues to consider. Rheum Dis Clin North Am. 2007;33:661-72. doi: 10.1016/j.rdc.2007.07.005

90. Hersh AO, Pang S, Curran ML, et al. The challenges of transferring chronic illness patients to adult care: reflections from pediatric and adult rheumatology at a US academic center. Pediatr Rheumatol Online J. 2009;7:13. doi: 10.1186/1546-0096-7-13

91. Falcini F, Nacci F. Systemic lupus erythematosus in the young: the importance of a transition clinic. Lupus. 2007;16:613-7. doi: 10.1177/0961203307078973

92. Foster HE, Minden K, Clemente D, et al. EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases. Ann Rheum Dis. 2017 Apr;76(4):639-46. doi: 10.1136/annrheumdis-2016-210112. Epub 2016 Nov 1.

93. Lee S-J, Silverman E, Joanne M, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol. 2011;7:718-29. doi: 10.1038/nrneph.2011.150

94. Floris A, Piga M, Mangoni AA, et al. Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. Mediat Inflam. 2018;2018:3424136. doi: 10.1155/2018/3424136

95. Uribe AG, Alarcon GS, Sanchez ML, et al. Systemic lupus erythematosus in three ethnic groups. XVIII. factors predictive of poor compliance with study visits. Arthritis Rheum. 2004;51:258-

96. doi: 10.1002/art.20226

97. Rojas-Serrano J, Cardiel MH. Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome. A cohort study. Lupus. 2000;9:601-6.

98. doi: 10.1191/096120300678828785

99. Koneru S, Kocharla L, Higgins GC, et al. Adherence to medications in systemic lupus erythematosus. J Clin Rheumatol. 2008;14:195-201. doi: 10.1097/RHU.0b013e31817a242a

100. M. R. Adherence to Pediatric Medical Regimens. Handbook of Child Psychology and developmental science. 7th ed. NY: John Wiley & Sons Inc; 2010.

101. Willems M, Haddad E, Niaudet P, et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr. 2006;148:623-7. doi: 10.1016/j.jpeds.2006.01.041

102. Polido-Pereira J, Ferreira D, Rodrigues AM, et al. Rituximab use in pediatric autoimmune diseases: four case reports. Ann N Y Acad Sci. 2009;1173:712-20. doi: 10.1111/j.1749-6632.2009.04804.x

103. Podolskaya A, Stadermann M, Pilkington C, et al. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child. 2008;93:401-6.

104. doi: 10.1136/adc.2007.126276

105. Nwobi O, Abitbol CL, Chandar J, et al. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol. 2008;23:413-9. doi: 10.1007/s00467-007-0694-9

106. Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum. 2005;52:3168-74. doi: 10.1002/art.21351

107. Watson L, Beresford MW, Maynes C, et al. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus. 2015;24:10-7. doi: 10.1177/0961203314547793

108. Баранов АА, редактор. Федеральные клинические рекомендации по оказанию медицинской помощи детям с системной красной волчанкой. Москва; 2015

109. Parikh S, Swaiman KF, Kim Y. Neurologic characteristics of childhood lupus erythematosus. Pediatr Neurol. 1995;13:198-201. doi: 10.1016/0887-8994(95)00186-J

110. Sibbitt WL, Brandt JR, Johnson CR, et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol. 2002;29:1536-42.

111. Turkel SB, Miller JH, Reiff A. Case series: neuropsychiatric symptoms with pediatric systemic lupus erythematosus. J Am Acad Child Adolesc Psychiatry. 2001;40:482-5.

112. doi: 10.1097/00004583-200104000-00018

113. Yu HH, Lee JH, Wang LC, et al. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: a 20-year study. Lupus. 2006;15:651-7. doi: 10.1177/0961203306070990

114. Lim LS, Lefebvre A, Benseler S, et al. Psychiatric illness of systemic lupus erythematosus in childhood: spectrum of clinically important manifestations. J Rheumatol. 2013;40:506-12.

115. doi: 10.3899/jrheum.120675

116. Loh WF, Hussain IM, Soffiah A, et al. Neurological manifestations of children with systemic lupus erythematosus. Med J Malaysia. 2000;55:459-63.

117. Singh S, Gupta MK, Ahluwalia J, et al. Neuropsychiatric manifestations and antiphospholipid antibodies in pediatric onset lupus: 14 years of experience from a tertiary center of North India. Rheumatol Int. 2009;29:1455-61. doi: 10.1007/s00296-009-0887-6

118. Brunner HI, Jones OY, Lovell DJ, et al. Lupus headaches in childhood-onset systemic lupus erythematosus: relationship to disease activity as measured by the systemic lupus erythematosus disease activity index (SLEDAI) and disease damage. Lupus. 2003;12:600-6. doi: 10.1191/0961203303lu430oa

119. Benseler SM, Silverman ED. Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus. 2007;16(8):564-71. doi: 10.1177/0961203307078971

120. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599-608. doi: 10.1002/1529-0131(199904)42:43.0.CO;2-F

121. Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69:2074-82. doi: 10.1136/ard.2010.130476

122. Avcin T, Benseler SM, Tyrrell PN, et al. A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis Rheum. 2008;59:206-13. doi: 10.1002/art.23334

123. Dos Santos MC, Okuda EM, Ronchezel MV, et al. Verbal ability impairment in juvenile systemic lupus erythematosus. Rev Bras Reumatol. 2010;50:362-74.

124. Mortilla M, Ermini M, Nistri M, et al. Brain study using magnetic resonance imaging and proton MR spectroscopy in pediatric onset systemic lupus erythematosus. Clin Exp Rheumatol. 2003;21:129-35.

125. Prismich G, Hilario MO, Len CA, et al. Use of single photon emission computed tomography and magnetic resonance to evaluate central nervous system involvement in patients with juvenile systemic lupus erythematosus. Braz J Med Biol Res. 2002;35:805-10. doi: 10.1590/S0100-879X2002000700007

126. Reiff A, Miller J, Shaham B, et al. Childhood central nervous system lupus; longitudinal assessment using single photon emission computed tomography. J Rheumatol. 1997;24:2461-5.

127. Russo R, Gilday D, Laxer RM, et al. Single photon emission computed tomography scanning in childhood systemic lupus erythematosus. J Rheumatol. 1998;25:576-82.

128. Szer IS, Miller JH, Rawlings D, et al. Cerebral perfusion abnormalities in children with central nervous system manifestations of lupus detected by single photon emission computed tomography. J Rheumatol. 1993;20:2143-8.

129. Dong J, Li H, Wang JB, et al. Predictors for neuropsychiatric development in chinese adolescents with systemic lupus erythematosus. Rheumatol Int. 2012;32:2681-6. doi: 10.1007/s00296-011-2042-4

130. Falcini F, De Cristofaro MT, Ermini M, et al. Regional cerebral blood flow in juvenile systemic lupus erythematosus: a prospective SPECT study. Single photon emission computed tomography. J Rheumatol. 1998;25:583-8.

131. Mostafa GA, Ibrahim DH, Shehab AA, et al. The role of measurement of serum autoantibodies in prediction of pediatric neuropsychiatric systemic lupus erythematosus. J Neuroimmunol. 2010;227(1-2):195-201. doi: 10.1016/j.jneuroim.2010.07.014

132. Mostafa GA, Nazif HK, El-Shahawi HH, et al. Antineuronal antibodies and electroneurophysiological studies in pediatric patients with neuropsychiatric systemic lupus erythematosus. Pediatr Allergy Immunol. 2009;20:192-9. doi: 10.1111/j.1399-3038.2008.00753.x

133. Papero PH, Bluestein HG, White P, et al. Neuropsychologic deficits and antineuronal antibodies in pediatric systemic lupus erythematosus. Clin Exp Rheumatol. 1990;8:417-24.

134. Press J, Palayew K, Laxer RM, et al. Antiribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis. Arthritis Rheum. 1996;39:671-6. doi: 10.1002/art.1780390420

135. Al-Obaidi M, Saunders D, Brown S, et al. Evaluation of magnetic resonance imaging abnormalities in juvenile onset neuropsychiatric systemic lupus erythematosus. Clin Rheumatol. 2016;35:2449-56. doi: 10.1007/s10067-016-3376-9

136. Gulati G, Jones JT, Lee G, et al. Altered Blood-Brain Barrier Permeability in Patients with systemic lupus erythematosus: a novel Imaging Approach. Arthritis Care Res. 2017;69:299-305. doi: 10.1002/acr.22923

137. Brunner HI, Klein-Gitelman MS, Zelko F, et al. Validation of the Pediatric Automated Neuropsychological Assessment Metrics in childhood-onset systemic lupus erythematosus. Arthritis Care Res. 2013;65:372-81. doi: 10.1002/acr.21835

138. Vega-Fernandez P, Vanderburgh White S, Zelko F, et al. Cognitive Performance scores for the Pediatric Automated Neuropsychological Assessment Metrics in Childhood Onset systemic lupus erythematosus. Arthritis Care Res. 2015;67:1119-274. doi: 10.1002/acr.22571

139. Thorbinson C, Oni L, Smith E, et al. Pharmacological management of childhood-onset systemic lupus erythematosus. Paediatr Drugs. 2016;18:181-95. doi: 10.1007/s40272-016-0170-8

140. Appenzeller S, Cendes F, Costallat LT. Epileptic seizures in systemic lupus erythematosus. Neurology. 2004;63(10):1808-12. doi: 10.1212/01.WNL.0000144178.32208.4F

141. Magro-Checa C, Zirkzee EJ, Huizinga TW, Steup-Beekman GM. Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. Drugs. 2016;76:459-83. doi: 10.1007/s40265-015-0534-3

142. Алексеева ЕИ, Дворяковская ТМ, Никишина ИП и др. Системная красная волчанка: клинические рекомендации. Часть 1. Вопросы современной педиатрии. 2018;17(1):19-37


Для цитирования:


Каледа М.И., Никишина И.П. Современные международные рекомендации по диагностике и лечению системной красной волчанки с ювенильным дебютом. Научно-практическая ревматология. 2018;56(4):405-415. https://doi.org/10.14412/1995-4484-2018-405-415

For citation:


Kaleda M.I., Nikishina I.P. CURRENT INTERNATIONAL GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS. Rheumatology Science and Practice. 2018;56(4):405-415. (In Russ.) https://doi.org/10.14412/1995-4484-2018-405-415

Просмотров: 311


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)